KCNRG – B‑cell Chronic Lymphocytic Leukemia

KCNRG (HGNC:18893) has been included in genomic studies investigating genetic alterations in B‑cell chronic lymphocytic leukemia (CLL; MONDO_0004948). In the study by Blood research (2020) (PMID:32747613), a cohort of 52 treatment‑naïve CLL patients was assessed using multiplex ligation‑dependent probe amplification (MLPA). Although the analysis reported genetic abnormalities in 34 (65%) patients, KCNRG was noted only as one of several genes interrogated without any detailed variant-level description or segregation analysis.

The absence of specific HGVS‑reported variants for KCNRG in this context limits the precision of the genetic evidence. There is no information regarding familial segregation or recurrent copy number changes uniquely attributable to KCNRG, which further restrains the overall certainty of the association. Consequently, while KCNRG is recurrently included in genetic panels for CLL, the evidence remains observational in nature.

In terms of genetic evidence, the available data are restricted to its inclusion within a broader screening approach. No definitive single nucleotide variant or copy number change with a clearly decipherable pathogenic role was described. This lack of detailed variant evidence means that the genetic contribution of KCNRG to CLL pathogenesis remains uncertain.

Regarding functional assessments, independent studies in hepatocellular carcinoma (PMID:16819283) have demonstrated that KCNRG may act as a tumor suppressor, as a missense mutation in this gene resulted in reduced suppressive effects on cell growth. However, these functional findings, while suggestive of a role in oncogenic processes, have not been corroborated in the context of CLL and therefore do not directly support KCNRG’s involvement in this hematological malignancy.

Overall, the present evidence linking KCNRG to B‑cell chronic lymphocytic leukemia is limited. The studies provide preliminary observational support largely driven by the gene’s inclusion in MLPA panels, yet lack detailed genetic and familial segregation data that would be necessary for a higher ClinGen scoring tier. Additional investigations including robust variant analyses and functional studies specific to CLL are needed to elucidate the precise role of KCNRG in this disease.

Key take‑home sentence: While KCNRG is recurrently evaluated in genetic screens for CLL, its current evidence base is limited, warranting further investigation before it can be reliably integrated into clinical diagnostic decision‑making.

References

• Blood research • 2020 • Genomic alterations in chronic lymphocytic leukemia and their correlation with clinico‑hematological parameters and disease progression PMID:32747613
• Experimental & molecular medicine • 2006 • Genetic and expression analysis of the KCNRG gene in hepatocellular carcinomas PMID:16819283

Evidence Based Scoring (AI generated)